Skip to main content
SpringerLink
Log in

Pramlintide

AC 137, ACO 137, Normylin, Symlin™, Tripro-amylin

  • Section 1: Type 2 Diabete Mellitus
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moyses C, Kolterman O, Mant T. Pharmacokinetics and hyperglycaemic effects of the amylin analogue AC-0137 in man. Diabet Med 1993 Oct; 10 Suppl. 3: 25

    Google Scholar 

  2. Moyses C, Kolterman O, Nuttall A, et al. First administration to man of the human amylin analogue tripro-amylin. Diabetologia 1994; 37 Suppl. 1: 72

    Google Scholar 

  3. Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996 Apr; 39: 492–9

    Article  PubMed  CAS  Google Scholar 

  4. Colburn WA, Gottlieb AB, Koda J, et al. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 1996 Jan; 36: 13–24

    PubMed  CAS  Google Scholar 

  5. Kong M-F, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998 May; 41: 577–83

    Article  PubMed  CAS  Google Scholar 

  6. Thompson RG, Peterson J, Gottlieb A, et al. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 1997 Apr; 46: 632–6

    Article  PubMed  CAS  Google Scholar 

  7. Amylin Pharmaceuticals. Amylin Pharmaceuticals announces initial phase III results are positive in type 1 diabetes and encouraging in type 2 diabetes. Media Release.: [4 pages], 15 Aug 1997

    Google Scholar 

  8. Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 1997 Nov; 40: 1278–85

    Article  PubMed  CAS  Google Scholar 

  9. Thompson RG, Gottlieb A, Organ K, et al. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 1997 Jul; 14: 547–55

    Article  PubMed  CAS  Google Scholar 

  10. Thompson RG, Pearson L, Schoenfeld S, et al. Pramlintide improved glycaemic control in patients with type 2 diabetes requiring insulin. Diabet Med 1997; 14 Suppl. 4: 22

    Google Scholar 

  11. What role for amylin in diabetes and its treatment? Drugs Ther Perspect 1996 Feb 5; 7 (2): 7–8

  12. Kolterman O, Kisicki JC, Peltier L, et al. Infusion of amylin agonist, AC-0137, reduces postprandial hyperglycemia in subjects with type 1 diabetes. Clin Res 1994 Feb; 42: 87A

    Google Scholar 

  13. Kolterman O, Glottlieb A, Moyses C. Amylin agonist, AC-137, reduces postprandial hyperglycemia in subjects with insulin dependent diabetes mellitus. Diabetes 1994; 43 Suppl. 1: 78

    Google Scholar 

  14. Kolterman OG, Gottlieb AB, Moyses CJ, et al. Administration of tripro-amylin reduces postprandial hyperglycemia in subjects with juvenile-onset diabetes. Diabetologia 1994; 37 Suppl. 1: 72

    Google Scholar 

  15. Kolterman OG, Gottlieb A, Moyses C, et al. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 1995 Aug; 18: 1179–82

    Article  PubMed  CAS  Google Scholar 

  16. Kolterman O, Whitehouse F, Ratner R, et al. Positive effects on body weight resulting from pramlintide therapy in type 1 and type 2 diabetes. Diabetologia 1998 Aug; 41 Suppl. 1: 214

    Google Scholar 

  17. Kong M-F, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997 Jan; 40: 82–8

    Article  PubMed  CAS  Google Scholar 

  18. Bloomgarden ZT. More on the treatment of type 2 diabetes. Diabetes Care 1999 Feb; 22: 357–61

    Article  PubMed  CAS  Google Scholar 

  19. Thompson RG, Pearson L, Schoenfeld SL, et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 1998 Jun; 21: 987–93

    Article  PubMed  CAS  Google Scholar 

  20. Ratner R, Levetan C, Schoenfeld S, et al. Pramlintide therapy in the treatment of insulin-requiring type 2 diabetes: results of a 1-year placebo-controlled study. Diabetes 1998 May; 47 Suppl. 1: 88

    Google Scholar 

  21. Ratner R, Levetan C, Schoenfeld S, et al. Effects of pramlintide therapy: a 1-year study in insulin-requiring type 2 diabetes. Diabetologia 1998 Aug; 41 Suppl. 1: 61

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pramlintide. Drugs R&D 2, 118–122 (1999). https://doi.org/10.2165/00126839-199902020-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902020-00010

Keywords

Search

Navigation